Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

  • Cheng A
  • Leiter L
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


PURPOSE OF REVIEW: In 2001, the Adult Treatment Panel III of the National Cholesterol Education Program issued recommendations, which were updated in 2004 to reflect knowledge from five major clinical trials completed after 2001. This review discusses the results of key clinical trials released in 2005 and their potential impact on the guidelines. RECENT FINDINGS: Three major clinical trials, one subgroup analysis, and one meta-analysis were published in 2005 that can potentially affect the existing guidelines. The Treating to New Targets and the Incremental Decrease in End Points Through Aggressive Lipid Lowering trials demonstrated the incremental benefit of more aggressive low-density cholesterol lowering in stable coronary heart disease. The Cholesterol Treatment Trialists' Collaboration meta-analysis of statin trials supported the importance of low-density lipoprotein cholesterol reduction, irrespective of initial lipid profile, in reducing cardiovascular events. A subgroup analysis of the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm demonstrated statin benefits in diabetes, whereas the Fenofibrate Intervention and Event Lowering in Diabetes study failed to show overall treatment benefits with a fibrate in diabetes. SUMMARY: Lowering of low-density lipoprotein cholesterol remains central in reducing cardiovascular risk; however, the recent trials support a target of less than 2.0 mmol/l (

Author-supplied keywords

  • Adult
  • Affect
  • Antihypertensive Agents
  • Antilipemic Agents
  • Canada
  • Cholesterol
  • Clinical Trials
  • Coronary Heart Disease
  • Diabetes Complications
  • Disease
  • Endocrinology
  • Evidence-Based Medicine
  • Guidelines
  • Health Knowledge,Attitudes,Practice
  • Heart
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypercholesterolemia
  • Knowledge
  • Meta-Analysis
  • Meta-Analysis as Topic
  • Patient Education as Topic
  • Patients
  • Practice Guidelines as Topic
  • Procetofen
  • Randomized Controlled Trials as Topic
  • Review
  • Risk
  • analysis
  • complications
  • diabetes
  • education
  • metabolism
  • patient
  • recommendations
  • targets
  • therapeutic use
  • therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • PMID: 16755211


  • A Y Cheng

  • L A Leiter

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free